BIOTECHNOLOGY VALUE FUND L P 13D and 13G filings for Rein Therapeutics Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-02-14 10:28 am Sale | 2023-12-31 | 13G | Rein Therapeutics Inc. RNTX | BIOTECHNOLOGY VALUE FUND L P | 0 0.000% | -236,835 (Position Closed) | Filing |
| 2023-02-14 11:42 am Purchase | 2022-12-31 | 13G | Rein Therapeutics Inc. RNTX | BIOTECHNOLOGY VALUE FUND L P | 236,835 5.200% | 236,835 (New Position) | Filing |